Purpose: The transitional cell carcinoma of the bladder (TCCB) is a rare disease below 35 years old patients. In our study, we aimed to present the treatment results and long-term follow-up process of younger patients.
Materials and Methods: A 20 patients aged between 11-35 years were reviewed ret-rospectively. Intravesical epirubicin or mito-mycin was administered to all of the patients within the first 12 hours in the postoperative period. The patiens were followed-up with cystoscopies according to the protocol. Ab-dominal computed tomography and Nuclear Matrix Protein-22 bladder control tests were performed once a year.
Results: Amyloidosis mimicked bladder tumor was detected in one patient and this patient was excluded from the study. The mean age of the 9 male and 10 female patients was calculated as 25.1 (11-35) years and the mean duration of follow-up was calculated as 67.4 (42-96) months. All of the patients had single tumoral focus and mean tumor size was cal-culated as 2.55 (1-4) centimeters. According to the TNM classification, 2 (10.5%) patients were reported as benign papilloma, 15 (78.9%) patients as Ta, and 2 (10.5%) patients as T1. Intravesical Bacillus Calmette Guerin (BCG) was administered to 2 (10.5%) patients whose pathologies were recorded as T1. After sixth doses of intravesical BCG, relapses occurred in these 2 patients. Intravesical BCG therapy was started again, and no relapses were observed in subsequent follow-ups. NMP-22 test yielded positive results only in 2 (10.5%) patients with relapses. In addition, progression was not ob-served in any of patients below 35 years old.
Conclucions: According to the related liter-ature and the clinical results of the current study, TCCB appears as low grade in younger ages with better prognosis at long-term follow-up.
Keywords: Bladder cancer; Pathology; Prognosis; Younger patient
Abstract
Purpose: The transitional cell carcinoma of the bladder (TCCB) is a rare disease below 35 years old patients. In our study, we aimed to present the treatment results and long-term follow-up process of younger patients.
Materials and Methods: A 20 patients aged between 11-35 years were reviewed ret-rospectively. Intravesical epirubicin or mito-mycin was administered to all of the patients within the first 12 hours in the postoperative period. The patiens were followed-up with cystoscopies according to the protocol. Ab-dominal computed tomography and Nuclear Matrix Protein-22 bladder control tests were performed once a year.
Results: Amyloidosis mimicked bladder tumor was detected in one patient and this patient was excluded from the study. The mean age of the 9 male and 10 female patients was calculated as 25.1 (11-35) years and the mean duration of follow-up was calculated as 67.4 (42-96) months. All of the patients had single tumoral focus and mean tumor size was cal-culated as 2.55 (1-4) centimeters. According to the TNM classification, 2 (10.5%) patients were reported as benign papilloma, 15 (78.9%) patients as Ta, and 2 (10.5%) patients as T1. Intravesical Bacillus Calmette Guerin (BCG) was administered to 2 (10.5%) patients whose pathologies were recorded as T1. After sixth doses of intravesical BCG, relapses occurred in these 2 patients. Intravesical BCG therapy was started again, and no relapses were observed in subsequent follow-ups. NMP-22 test yielded positive results only in 2 (10.5%) patients with relapses. In addition, progression was not ob-served in any of patients below 35 years old.
Conclucions: According to the related liter-ature and the clinical results of the current study, TCCB appears as low grade in younger ages with better prognosis at long-term follow-up.
Keywords: Bladder cancer; Pathology; Prognosis; Younger patient